Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 161

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 161
---
.2 million increase in accrued interest on marketable securities, partially offset by a $1.1 million increase in accounts payable and accrued expenses related to
timing of payments and clinical trial expenses.

Investing Activities

Cash provided by investing activities for the six months ended June 30, 2025 was $5.0 million primarily related to proceeds from the sales and
maturities of marketable securities.

Cash used in investing activities for the six months ended June 30, 2024 was $19.2 million primarily
related to $29.7 million for the purchase of marketable securities to invest our excess cash, partially offset by $10.7 million in maturities of marketable securities.

Cash provided by investing activities for the year ended December 31, 2024 was $23.2 million primarily related to proceeds from the sales
and maturities of marketable securities, partially offset by the purchase of marketable securities to invest our excess cash.

Cash used
in investing activities for the year ended December 31, 2023 was $28.0 million related to the purchase of marketable securities to invest our excess cash, partially offset by maturities of marketable securities.

Financing Activities

Cash provided by
financing activities for the six months ended June 30, 2024 was $38.3 million primarily related to the proceeds from the issuance of redeemable convertible Series C preferred stock, net of issuance costs.

Cash provided by financing activities for the year ended December 31, 2024 was $38.3 million primarily related to the proceeds from the
issuance of redeemable convertible Series C preferred stock, net of issuance costs.

106

Cash provided by financing activities for the year ended December 31, 2023 was $33.7 million related to $33.0 million in proceeds from the issuance of redeemable convertible Series C preferred stock, net of issuance costs, and $0.6 million in proceeds from the issuance of convertible notes, net of issuance costs. Future Funding Requirements We expect our expenses to increase substantially in connection with our ongoing activities, in particular as we continue to advance LB-102and any of our future product candidates through clinical trials. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. As of June 30, 2025, we had cash and cash equivalents of $14.2 million. Based on our current plans, we believe that our existing cash